BNIPL

Across TCGA pan-cancer cohorts, BNIPL mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of BNIPL’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where BNIPL mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BNIPL is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC and LSCC are the cancer types where BNIPL tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BNIPL mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−1.356	<.001	11	view →
LSCC	All	All	−0.277	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

BNIPL–HNSC

Open the HNSC breakdown →